Angelalign Technology Inc's 1H26 preliminary results beat expectations across the board

Overview

Morgan Stanley commented on Angelalign Technology Inc's (6699.HK) 1H26 earnings guidance. The report believes that the company's revenue, domestic volume, overseas volume and net profit all exceeded targets or forecasts, with domestic operating margins expected to remain resilient and overseas losses likely to narrow further. Despite the positive earnings reaction, the report's impact on the existing investment thesis is "Unchanged," and the stock rating remains Equal-weight.

Core views

The core views are: first, 1H26 revenue growth was significantly faster than Morgan Stanley's forecast; second, China volume growth clearly exceeded the full-year target, but ASP is expected to decline by a mid-to-high single-digit percentage due to changes in case mix; third, overseas volume remained strong, and price increases for certain new cases in Europe did not disrupt volume growth, indicating improved brand recognition; fourth, net profit was significantly above forecast, mainly driven by resilient margins in China and narrower overseas losses.

Analysis framework

The report compares the earnings guidance with Morgan Stanley's forecasts, management targets and market consensus, focusing on trends in revenue, volume, ASP, net profit and margins, while assessing the direction of EPS expectations over the next 12 months based on domestic and overseas segment performance.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow

  The base case is derived from DCF, using an 11% WACC and a 3% perpetual growth rate, with the DCF model beginning in 2026.

• Forecasting systemMorgan Stanley ModelWare

  Internal forecasting model

  Unless otherwise stated, the report's metrics are based on the Morgan Stanley ModelWare framework; some consensus data are from Refinitiv Estimates.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Angelalign Technology Inc (6699.HK)

  Research subject, Hong Kong-listed company

  Strengths

  1H26 revenue, volume and net profit all exceeded expectations; overseas volume was strong; price increases in Europe did not affect growth; domestic margins are expected to remain resilient.

  Weaknesses

  China ASP is expected to decline by a mid-to-high single-digit percentage due to changes in case mix; the rating remains Equal-weight, with only approximately 5% target price upside.

  Comparison

  Compared with Morgan Stanley's forecasts, the company's 1H26 revenue of US$229-231mn was above the US$207mn forecast, and net profit of US$24.0-25.4mn was above the forecast of approximately US$13mn.

  Risks

  Greater-than-expected expansion and impact of VBP, loss of domestic market share, China or overseas margins coming under pressure due to competition, and slower-than-expected overseas volume ramp-up.

Key data

• 1H26 revenue guidanceUS$229-231mnUp 41.9-43.1% year over year, above Morgan Stanley's forecast of US$207mn and 28% year-over-year growth.
• China volumeApproximately 148.6k casesUp 36.8% year over year, significantly above the FY26 target of 18% year-over-year growth; ASP is expected to decline by a mid-to-high single-digit percentage due to changes in case mix.
• Overseas volumeApproximately 168k casesUp 43.3% year over year, above management's FY26 target of 33% year-over-year growth; overseas ASP is expected to increase by a low single-digit percentage.
• Preliminary net profitUS$24.0-25.4mnUp 69.0-78.9% year over year, above Morgan Stanley's forecast of approximately US$13mn.
• Target price and closing priceHK$84.00 / HK$79.90The target price implies approximately 5% upside from the July 31 closing price.
• Financial forecasts2026e revenue US$451mn, EPS US$0.30The table lists 2026e, 2027e and 2028e revenue of US$451mn, US$542mn and US$645mn, respectively.

Impact & implications

The earnings guidance reinforces the company's execution capabilities in domestic recovery and overseas expansion. In particular, the continued strong volume growth after overseas price increases indicates improvements in brand and channel capabilities. This could prompt the market to raise consensus EPS estimates for the next 12 months in the near term, but with the rating remaining Equal-weight and limited target price upside, the report signals a combination of fundamental outperformance and relatively limited valuation upside.

Risks

• VBP expansion and impact greater than expected.
• Loss of domestic market share.
• Margins in China or overseas markets coming under severe pressure due to intensified competition.
• Slower-than-expected overseas volume ramp-up.

What to watch

• Whether FY26 domestic volume can maintain growth above the 18% target.
• Whether overseas volume can remain above the 33% target and validate brand resilience after price increases.
• The magnitude of the decline in China ASP and changes in case mix.
• Progress in narrowing overseas losses and the timing of breakeven.
• Whether consensus EPS for the next 12 months is revised moderately upward.